Skip to content
Back to Investors
BGF

BGF

Venture Capital

BGF is one of the largest and most experienced growth capital investors operating across the UK and Ireland.


Recent investments

£7.5M

The funding round was led by BGF and Downing to support the rollout of the company's respiratory diagnostics business.

"COPD is the third leading cause of death in the world and prevalence of respiratory diseases is rising. But the current clinical pathway for COPD diagnostics is stuck in the 1800s and is ineffective, inefficient and expensive. In England alone, the NHS estimates that a third of people with hospital admissions from COPD have not been diagnosed, by which point their disease has progressed, their quality of life has deteriorated and the cost to the healthcare system has ballooned."
— Ameera Patel, Chief executive
Seed
£2.9M

The UCL spinout secured backing from BGF and UCL Technology Fund to advance its rapid battery charging technology.

"The electrification of transport will be a big part of society’s journey towards a low carbon economy. That journey must be accomplished without delay, so it is imperative that we identify and remove the biggest barriers to EV adoption as quickly as possible. Range anxiety and long charging times are at the top of the list for attention and Gaussion’s new fast-charge technology promises to remove them"
— John Miles, Chair
Growth
£9.0M

Growth capital from BGF will back software development and the Caseload Manager tool at Voicescape.

"The social housing and local authority sectors have displayed a remarkable appetite for digital transformation over the last few years, which was only accelerated by the pandemic. The constantly changing needs and circumstances of residents have been highlighted, making it crucial for organisations to use technology effectively. Voicescape’s solutions have been focused on helping organisations use technology to better understand their customers’ behaviours and improve engagement at scale, especially when faced with these strategic challenges."
— John Doyle, Founder
Series A
£13.0M

The financing round was led by Oxford Science Enterprises and will support market expansion in the UK, EU, and United States.

"We are thrilled that five successful institutional investors participated in the financing round which validates the vast clinical and business potential of Caristo’s innovations"
— Oran Muduroglu, Board Chairman